US Stock MarketDetailed Quotes

NONOF NOVO NORDISK A/S

Watchlist
  • 109.567
  • -1.972-1.77%
15min DelayTrading Nov 4 14:10 ET
487.58BMarket Cap37.57P/E (TTM)

About NOVO NORDISK A/S Company

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsv?rd, Denmark.

Company Profile

SymbolNONOF
Company NameNOVO NORDISK A/S
Listing DateJul 9, 1981
Founded1931
CEOMr. Lars Fruergaard Jorgensen
MarketPink Market
Employees64319
Fiscal Year Ends12-31
AddressNovo Allé 1
CityBagsv?rd
ProvinceCapital Region
CountryDenmark
Zip Code2880
Phone45-44-44-88-88

Company Executives

  • Name
  • Position
  • Salary
  • Lars Fruergaard Jorgensen
  • Chief Executive Officer and President
  • --
  • Marcus Schindler, PhD
  • Executive Vice President, Research and Early Development and Chief Scientific Officer
  • 23.60M
  • Karsten Munk Knudsen
  • Executive Vice President and Chief Financial Officer
  • 26.40M
  • Doug Langa
  • Executive Vice President, North America Operations
  • 2.20M
  • Martin Holst Lange
  • Executive Vice President, Development
  • 23.40M
  • Ludovic Helfgott
  • Executive Vice President, Rare Disease
  • 2.20M
  • Maziar Mike Doustdar
  • Executive Vice President, International Operations
  • 2.20M
  • Henrik Ehlers Wulff
  • Executive Vice President, Product Supply, Quality Assurance, Digital Data and IT
  • 25.90M
  • Camilla Sylvest
  • Executive Vice President, Commercial Strategy and Corporate Affairs
  • 23.40M
  • Helge Lund
  • Chairman of the Board
  • 3.90M
  • Henrik Poulsen
  • Vice Chairman of the Board
  • 2.40M
  • Thomas Rantzau
  • Director
  • 1.10M
  • Mette Bojer Jensen
  • Director
  • 1.30M
  • Liselotte Hyveled
  • Director
  • 1.10M
  • Elisabeth Dahl Christensen
  • Director
  • 1.10M
  • Kasim Kutay
  • Director
  • 1.30M
  • Christina Law
  • Independent Director
  • 1.70M
  • Dr. Sylvie Gregoire,Pharm.D.
  • Independent Director
  • 2.00M
  • Laurence Debroux
  • Independent Director
  • 2.10M
  • Andreas Fibig
  • Independent Director
  • 1.40M
  • Dr. Martin W. Mackay, PhD
  • Independent Director
  • 1.80M
  • David Moore
  • Executive Vice President, Corporate Development
  • 2.20M
  • Tania Sabroe
  • Executive Vice President, People and Organisation
  • 2.20M

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data